Effects of proton pump inhibitor therapy in the distal gut: Putting the pieces together

Digestive Diseases and Sciences

Volumn 57, Issue 10, 2012, Pages 2487-2489

  Keszthelyi, Daniel ^a   Masclee, Ad A ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; ESOMEPRAZOLE; LANSOPRAZOLE; MYOSIN ADENOSINE TRIPHOSPHATASE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

BACTERIAL OVERGROWTH; CYANOCOBALAMIN DEFICIENCY; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; HYPOMAGNESEMIA; INTESTINE; INTESTINE FLORA; IRON DEFICIENCY; NONHUMAN; PH; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

COLITIS; COLON; FEMALE; HUMANS; INTESTINAL MUCOSA; LYMPHOCYTES; MALE; PROTON PUMP INHIBITORS;

EID: 84867887437     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2339-5     Document Type: Review

References (20)

1. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2-3.
2. van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD. Sociodemographic factors influence chronic proton pump inhibitor use by a large population in The Netherlands. Aliment Pharmacol Ther. 2009;29:571-579.
3. Stichting FarmaceutischeKerngetallen. Facts and figures 2011, 2012. Available at: http://www.sfk.nl/pdf-documenten/data-en-feiten/dataen- feiten-2011. Accessed July 6, 2012.
4. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122:896-903.
5. Kwok CS, Nijjar RS, Loke YK. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis. Drug Saf. 2011;34: 47-57.
6. Food and Drug Administration Drug Safety Communication. Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Available at: http://www.fda.gov/Drugs/ DrugSafety/ucm290510.htm. Accessed July 6, 2012.
7. Vesper BJ, Jawdi A, Altman KW, Haines GK III, Tao L, Radosevich JA. The effect of proton pump inhibitors on the humanmicrobiota. Curr Drug Metab. 2009;10:84-89.
8. Yu Y, Han, DS, Choi EY et al. Is use of PPIs related to increased intraepithelial lymphocytes in the colon? Dig Dis Sci. 2012. (Epub ahead of print). doi:10.1007/s10620-012-2315-0.
9. Poullis A, Foster R, Mendall MA, Shreeve D, Wiener K. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol. 2003;15:573-574; author reply 574.
10. Lewis SJ, Franco S, Young G, O'Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10:557-561.
11. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8:504-508.
12. Ratuapli SK, Ellington TG, O'Neill MT, et al. Proton pump inhibitor therapy use does not predispose to small intestinalbacterial overgrowth. Am J Gastroenterol. 2012;107:730- 735.
13. Spiegel BM. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol. 2011;9:461-469; quiz e459.
14. Rechkemmer G, Frizzell RA, Halm DR. Active potassium transport across guinea-pig distal colon: action of secretagogues. J Physiol. 1996;493:485-502.
15. Mullin JM, Gabello M, Murray LJ, et al. Proton pump inhibitors: actions and reactions. Drug Discov Today. 2009;14:647-660.
16. Murray LJ, Gabello M, Rudolph DS, et al. Transmucosal gastric leak induced by proton pump inhibitors. Dig Dis Sci. 2009;54: 1408-1417.
17. Mullin JM, Valenzano MC, Whitby M, et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther. 2008;28:1317-1325.
18. Burgel N, Bojarski C, Mankertz J, Zeitz M, Fromm M, Schulzke JD. Mechanisms of diarrhea in collagenous colitis. Gastroenterology. 2002;123:433-443.
19. Riordan SM, McIver CJ, Thomas DH, Duncombe VM, Bolin TD, Thomas MC. Luminal bacteria and small-intestinal permeability. Scand J Gastroenterol. 1997;32:556-563.
20. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1314-1322.